Cleveland Diagnostics

Cleveland Diagnostics, Inc. is a biotechnology company with the slogan “Cleveland Diagnostics offers novel, more accurate testing for early detection of cancer and risk of high-grade disease.” Since its establishment in 2013, the company has been committed to developing groundbreaking technology for the early detection of cancer. They aim to introduce a new class of diagnostic tests with high sensitivity and specificity for various cancers, allowing for early detection when cancer is most treatable. The company is headquartered in the United States. Cleveland Diagnostics recently secured a significant $75.00M investment in a Private Equity Round led by Novo Holdings on 17 January 2024. This substantial investment reflects the confidence of investors in the potential of the company's technology and its impact on the field of cancer diagnostics. By focusing on cutting-edge technology and innovation in the biotechnology and healthcare industries, Cleveland Diagnostics is poised to make substantial contributions to cancer detection and treatment. With strong financial backing from prominent investors, the company is well-positioned to drive forward their mission of enabling early and more accurate detection of cancer, ultimately improving patient outcomes.